Background-Under normoxic conditions, hypoxia-inducible factor (HIF)-1␣ is rapidly degraded by 2 hydroxylases:
C oronary artery disease is the leading cause of morbidity and mortality in the Western world. 1 Despite conventional treatments, a significant number of patients still have refractory angina. 2 Cytokine agents are a promising therapeutic option, which can be used as adjunctive treatment to revascularization or cell therapy. Cytokine therapy may act directly on the myocardium (eg, inhibiting apoptosis and stimulating proliferation) or indirectly by mobilization of stem cells from the systemic circulation. 3 However, randomized clinical trials have shown mixed results, which may be partly due to the limited benefits of single gene therapy. 4 A better option may be to administer hypoxia-inducible factor (HIF)-1␣, an upstream transcriptional factor that regulates Ͼ100 genes and protects the myocardium from ischemic injury. 5, 6 Unfortunately, HIF-1␣ has a biological half-life of only Ϸ5 minutes under normoxic conditions. Its rapid proteosomal degradation results from hydroxylation of HIF-1␣ at Pro 402 or Pro 564 by a set of HIF prolyl hydroxylase (PHD) isoenzymes (1 to 3) that mediate its recognition by von Hippel-Lindau ubiquitin ligase complex. 7 Concurrently, factor-inhibiting HIF-1 (FIH) also catalyzes the hydroxylation of HIF-1␣ Asn 803 , which blocks its interaction with the transcriptional coactivator p300. 8 In contrast, during hypoxia, the lack of hydroxylase activities enables HIF-1␣ to escape proteosomal destruction and allows it to bind with the HIF-1␤ subunit to become transcriptionally active.
In this study, we used short hairpin (sh) sequences inserted into a novel, nonviral, minicircle vector to inhibit PHD isoenzyme 2 (shPHD2) and FIH (shFIH), which then prevented HIF-1␣ degradation. We found that upregulation of HIF-1␣ enhances stem cell mobilization (through molecular imaging and fluorescence-activated cell sorting [FACS] ) and increases myocardial angiogenesis (through laser-capture microdissection [LCM] and immunohistochemistry), leading to significant improvement in cardiac function after myocardial infarction (MI).
Methods

RNA Interference of Mouse PHD2 Gene in Culture Cell
Mouse PHD2 and FIH genes were cloned from mouse embryonic stem cells (SV129 line). We used the PHD2 isoenzyme because a previous study showed higher expression of PHD2 in the heart compared to PHD1 or PHD3 isoenzymes. 9 We designed 4 sequences of RNA interference sites for the PHD2 gene and 8 for the FIH gene. The targeting sequences are shown in online-only Data Supplement Figure I . The optimal knockdown fragment was inserted after the H1 promoter in the minicircle parental backbone vector.
Cell Culture, shRNA Transfection, and Hypoxia Exposure
Mouse C2C12 myoblasts were cultured in DMEM medium (high glucose)ϩ10% FBS. Mouse HL-1 atrial myocytes were cultured in 10% FBS (BioWhittaker), 10 g/mL insulin (Life Technologies), 50 g/mL endothelial cell growth supplement (Upstate Biotechnology), 1 mol/L retinoic acid (Sigma), 10 mol/L norepinephrine (Sigma), 100 U/mL penicillin, 100 g/mL streptomycin (Life Technologies), and an additional 1ϫ nonessential amino acids (Life Technologies) on 0.01% gelatin-coated plate. Mouse c-kit ϩ cardiac progenitor cells (CPCs) were isolated based on a previously described protocol. 10 CPCs were cultured in 10% embryonic stem cell-qualified FBS (Gibco), DMEM, Ham F-12 medium, insulin-transferrin-selenium, 10 ng/mL leukemia inhibitory factor, 10 ng/mL basic fibroblast growth factor (bFGF), 20 ng/mL epidermal growth factor, and penicillin-streptomycin-glutamine. Minicircle vectors with shPHD2 and shFIH driven by H1 promoter were cotransfected into mouse C2C12, HL-1, and CPC using lipofectamine 2000 (Invitrogen), with the plasmid pHRE-SV40-FLuc as control for determining knockdown efficiency (online-only Data Supplement Figure I ). After minicircle shRNA transfection, cells were cultured for 1 day before being subjected to the hypoxia condition with 5% CO 2 , 1% O 2 , and 94% N 2 at 37°C for 48 hours.
Quantitative Polymerase Chain Reaction Analysis of Angiogenesis Genes
At the end of the 48-hour hypoxia treatment, cells were harvested for immediate RNA extraction (nϭ3 biological replicates 
Angiogenesis Cytokine Array After Hypoxia Exposure
At the end of the hypoxic treatment, the supernatant was collected for angiogenesis cytokine array (Panomics). In 2 separate experiments (duplicate spots, 2 biological replicates), the arrays were hybridized and imaged together. Expression intensities were calculated by adding the total pixel intensity for each spot. Interarray normalization was performed by using positive control spots (8 per array) on each array. Protein expression levels were normalized to PBS controls so that changes in protein expression could be easily assessed.
Animal Surgery To Induce MI
Ligation of the mid-left anterior descending coronary artery was performed in adult female FVB mice (Charles River Laboratories; Wilmington, MA) by a single experienced microsurgeon (Y.G.). Survival rate for each surgery group was between 80% to 90%. MI was confirmed by myocardial blanching and ECG changes. Animals were randomized into shFIH (nϭ15), shPHD2 (nϭ15), shPHD2ϩshFIH (nϭ15), and shScramble control (nϭ15) groups. Animals were injected intramyocardially with 25 g of shRNA or shScramble minicircle vector using a 31-gauge Hamilton syringe. In all groups, the volume of injection was 25 L in 3 different spots near the periinfarct zone. Study protocols were approved by the Stanford Animal Research Committee.
Activation of Endogenous c-kit
؉ CPCs With shRNA Therapy
For immunostaining, frozen heart sections (nϭ5 mice per group) were deparaffinized, and antigen retrieval was performed using 10 mmol/L citrate (pH 6.0). Slides were blocked in TNB (PerkinElmer) for 1 hour after which goat antimouse c-kit antibody (R&D Systems) was added (1:100) overnight at 4°C. Slides were washed in 1 mol/L Tris/NaCl followed by secondary antibody incubation for 2 hours at room temperature. 11 For FACS of c-kit ϩ CPCs in the heart (nϭ5 mice per group), we excised the periinfarct zone and digested it using 0.1% collagenase IV into single-cell suspension. FACS was performed using c-kit (allophycocyanin-Cy7 conjugated; BD Biosciences) antibody as previously described. 12 
Creation of Bone Marrow Chimeric Mouse Model
To determine whether c-kit ϩ cells found in the heart were endogenous or donor-derived bone marrow-derived cells, we generated a hematopoietic chimeric mouse model that we termed the mousenized mouse model. Using a strategy described previously, we used lineage-negative bone marrow cells (BMCs) from C57BL/6 mice (major histocompatibility complex [MHC] class I haplotype, H2k b ) to reconstitute NOD/SCID IL-2Rg (Ϫ/Ϫ) mice (MHC class I haplotype, H2g 7 ), a severely immunocompromised strain that lacks T cells, B cells, and NK cells. 13 Briefly, 2-to 3-day-old NOD/SCID IL-2Rg (Ϫ/Ϫ) pups received myeloablative treatment consisting of 100 cGy gamma irradiation. Sixteen hours later, pups received an intrahepatic injection of 1ϫ10 6 lineage-negative BMCs isolated from adult C57BL/6 mice. Six to 8 weeks later, hematopoietic engraftment was confirmed by detecting engraftment of donorderived (H2k bϩ ) multilineage immune cells in peripheral blood of mousenized mice through FACS. After donor cell engraftment was confirmed, the mousenized mice underwent left anterior descending coronary artery ligation followed by injection of shPHD2ϩshFIH versus shScramble into the periinfarct zone (nϭ3 mice per group). Cells harvested from the periinfarct zone were stained with allophycocyanin-conjugated c-kit and R-phycoerythrin-conjugated H2k b antibodies. Donor-derived c-kit cells were identified by FACS as c-kit ϩ and H2k bϩ .
Analysis of Angiogenesis Genes Using LCM and RNA Extraction
Murine hearts were removed after perfusion with 20 mL PBS, embedded in optimal cutting temperature, and immediately frozen in liquid nitrogen. Seven thick tissue sections of left ventricle were prepared on polyethylene naphthalate membrane-coated slides (MicroDissect GmbH). For LCM, slides were thawed briefly and air dried 5 minutes before dissection. Green fluorescence observed under laser microscopy was used as a landmark for microdissection. Specific green fluorescence tissues, as well as normal cardiac tissues without green fluorescence, were independently dissected out by applying Leica LCM Systems (MicroDissect GmbH). The dissected tissues were placed on the caps of microcentrifuge tubes with 5 L lysis enhanced buffer. After dissection, tissues were collected by centrifugation at 8000g for 5 minutes. Total RNA extraction and reverse transcription of these samples were performed using a commercial 1-step kit (Invitrogen) (nϭ5 mice per group).
Statistical Analysis
For calculation of relative gene expression, the expression level of each specific gene was divided by the expression level of GADPH. For statistical analyses of treatment groups, a Box-Cox transformation was used to achieve approximate normality for analysis by ANOVA and repeated-measures ANOVA. ANOVA (1 tail, equal variance) with post hoc testing was used to analyze qPCR, angiogenesis cytokine array, and myocardial perfusion. Repeatedmeasures ANOVA was used to analyze MRI, bioluminescence imaging, and echocardiographic data. Differences were considered significant at PϽ0.05. Unless otherwise specified, data are expressed as meanϮSD.
Results
In Vitro Characterization of shFIH and shPHD2 Double Knockdown
We measured activation of HIF-1␣ and subsequent upregulation of angiogenesis genes after hydroxylase inhibition using shRNAs under normoxic and hypoxic conditions. Plasmid hypoxia response element pHRE-SV40-FLuc is a hypoxia-sensing 5xHRE-SV40 promoter driving FLuc cassette. The 5 copies of HRE derived from the erythropoietin gene are activated through binding of the HIF-1 complex, 14 which allowed us to monitor the efficacy of the upstream shRNA knockdown compared to shScramble control ( Figure  1A ). 2 /sr), indicating increased binding of 5xHRE-SV40 promoter by HIF-1␣ after double shRNA knockdown. A similar, but more robust trend was observed when the cells were exposed to hypoxic conditions. This is an expected finding given that HIF-1␣ acts by binding to the HREs to drive the expression of FLuc under hypoxic conditions. Western blot confirmed that higher levels of HIF-1␣ expression are present under hypoxic conditions, as shown in online-only Data Supplement Figure II .
To quantify luciferase activity, we lysed the cells and determined the luminescence activity normalized to protein concentration (online-only Data Supplement Figure III) . The luminescence activity was highest in the double-knockdown group under both normoxic (2495Ϯ55 luminescence activity/mg protein) and hypoxic conditions (5232Ϯ100 luminescence activity/mg protein). To confirm similar effects in different cell types, mouse HL-1 atrial myocytes and mouse 
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c-kit ϩ CPCs also were transfected by minicircle shRNA and pHRE-SV40-FLuc. Comparable results were observed in these 2 cell types (online-only Data Supplement Figure IV) .
To confirm the pHRE-SV40-FLuc imaging signals, mRNA was isolated and qPCR performed for detection of HIF-1␣ and downstream angiogenesis genes. As shown in Figure 1B , relative expression of 6 genes related to angiogenesis (eg, bFGF, VEGF, Flt, KDR, TGF, PAI-1) were increased by 28.8Ϯ5.3% and 54.3Ϯ8.6% after treatment with shPHD2 and double knockdown, respectively. HIF-1␣ mRNA levels were not changed, which is expected because shRNA affects HIF-1␣ at the protein and not at the mRNA level. HIF-1␣ protein can activate several downstream genes responsible for stimulation of angiogenesis. 15 To examine whether upregulation of HIF-1␣ protein through shRNA knockdown of PHD2 and FIH also can exert similar effects, supernatant from transfected C2C12 cells was used for angiogenesis assays. Figure 1C and 1D show significant upregulation of several angiogenesis activators (eg, FGF␣, IL-6, leptin, VEGF, tumor necrosis factor-␣, and TGF-␣) after double knockdown.
Interestingly, both IFN-␥ and tissue inhibitor of metalloproteinase-1 (TIMP-1) also were upregulated in the double-knockdown group ( Figure 1D) . IFN-␥ is a soluble cytokine, which has antiviral, immunoregulatory, and antitumor properties. 16 In contrast, TIMP-1 is a 28-kDa protein that inhibits the function of metalloproteinases and has been associated with cell growth promotion, matrix binding, apoptosis induction, and angiogenesis regulation. 17 Previous studies have shown that HIF-1␣ regulates IFN-␥ and TIMP-1. 18 -22 To confirm this, we measured the relative expression of TIMP-1 after transfection of C2C12 cells with a minicircle carrying the following genes: (1) HIF-1␣ (positive control), (2) an inhibitor of HIF-1␣ (siHIF-1␣), (3) shFIH and shPHD2 (double knockdown), and (4) blank vector (negative control). We found that siRNA inhibition of HIF-1␣ led to significantly lower TIMP-1 and IFN-␥ expression levels. In contrast, overexpression of minicircle HIF-1␣ and minicircle shPHD2ϩshFIH led to significantly higher levels of TIMP-1 (PϽ0.001 for both) and IFN-␥ (PϽ0.05 for both) compared with control (online-only Data Supplement Figure V) . Consistent with these findings, Yang et al 23 demonstrated that shRNA inhibition of HIF-1␣ can dramatically decrease the expression of TIMP-1 mRNA expression and protein levels. Taken together, these data confirm that similar to physiological hypoxia response, PHD2ϩFIH double knockdown can effectively stabilize HIF-1␣ protein and induce HIF-1␣-dependent gene activation in vitro.
Improvement of Left Ventricular Function and Perfusion After Dual shRNA Therapy
To examine whether double shRNA knockdown therapy can synergistically improve cardiac function, cardiac MRI was performed. At weeks 4 and 8 after MI, significant improvement in left ventricular ejection fraction (LVEF) was seen in the double-knockdown group compared to the other groups ( Figure 2 ). The shPHD2 knockdown group also had improvement in LVEF compared with the shScramble group at weeks 4 and 8. These findings also were confirmed by serial ECGs (online-only Data Supplement Figure VI) . In addition, invasive hemodynamic parameters showed that the increase in LVEF was associated with lower left ventricular end-diastolic volume and left ventricular end-systolic volume in double shRNA knockdown compared with shScramble (online-only Data Supplement Figure VII) . Finally, shPHD2ϩshFIH treatment improved myocardial perfusion as determined by measuring the distribution of fluorescent microspheres within myocardial tissues after injection into the left ventricular cavity (online-only Data Supplement Figure VIII) . These results also coincide with observed differences in HIF-1␣ expression at weeks 4 and 8 in the shPHD2ϩshFIH group compared with the other groups (online-only Data Supplement Figure IX) . 
Double Knockdown Enhances BMC Homing to the Injured Myocardium
Previous studies have demonstrated that stem cells are activated and enriched in areas of injury. 24, 25 Moreover, cytokines have been shown to improve the cardiac stem cell mobilization in the infarction area. 12 To confirm angiogenesis-related cytokine function for stem cell homing, BMCs were isolated from transgenic mouse that constitutively express green fluorescent protein (GFP) and FLuc and intravenously injected into syngeneic FVB mice with MI and shRNA therapy. Double knockdown significantly increased the number of BMC recruited to the myocardium from days 1 to 28 as assessed by longitudinal bioluminescence imaging ( Figure 3A and 3B ). GFP and troponin T double staining also demonstrated more GFP ϩ cells in the shPHD2ϩshFIH group (online-only Data Supplement Figure X) .
Double Knockdown Activates c-kit ؉ CPCs
Next, we assessed whether double knockdown also can induce proliferation of c-kit ϩ CPCs. Immunostaining showed higher presence of c-kit ϩ CPCs near the periinfarct area in the shPHD2ϩshFIH group ( Figure 4A) . To validate the histological data, we then performed FACS analysis for c-kit ϩ CPCs after excision of the periinfarct tissue and digestion into single-cell suspension. FACS confirmed that the number of c-kit ϩ CPCs was significantly greater in the shPHD2ϩshFIH group than in shScramble control ( Figure 4B and 4C) . To analyze the source of c-kit ϩ cells, a bone marrow chimeric mouse model (mousenized mouse model) was created. 13 The 
Ex Vivo Histological Analysis Confirmed In Vivo Functional Data
After imaging, animals were euthanized and their hearts explanted. Hematoxylin-eosin staining showed thicker heart wall size for the shPHD2ϩshFIH group than for the shScramble control ( Figure 5A ), confirming the positive functional data seen by MRI, echocardiography, and pressure-volume loop. Minicircle vector containing shPHD2ϩshFIH significantly decreased left ventricular scarring compared with shFIH and shScramble control ( Figure  5B ). Immunohistochemistry of the periinfarct region by CD31 staining also showed the highest neovascularization in the shPHD2ϩshFIH group (615Ϯ57 vessels/mm 2 ) compared with the other 2 treated groups (shPHD2, 478Ϯ36 vessels/ mm 2 ; shFIH, 231Ϯ18 vessels/mm 2 ), with the lowest neovascularization in the shScramble group (179Ϯ23 vessels/mm 2 ) (PϽ0.05 compared with shFIH and shScramble; PϽ0.01 compared with shPHD2) ( Figure 5C ). To analyze the in vivo transfection efficiency of the minicircle vector, we injected minicircle GFP into the periinfarct zone of murine hearts. Cells were harvested 1 week later and stained with mouse cardiac troponin T and CD31 antibody for cardiac and endothelial cells, respectively. FACS analysis indicated that there were 10.1Ϯ1.4% GFP ϩ /troponin T ϩ cells and 2.7Ϯ0.4% GFP ϩ /CD31 ϩ cells (data not shown). Overall, these data demonstrate that minicircle can efficiently transfect cardiac cells in vivo, which is consistent with the in vitro transfection data on HL-1, H9c2, and CPC shown in Figure  1A and online-only Data Supplement Figure IV .
Double Knockdown Promotes Angiogenesis and HIF-1␣ Stabilization in Myocardial Tissues
To further elucidate the mechanisms of shPHD2 and shFIH therapy, we harvested the periinfarct area tissue by LCM and performed qPCR of angiogenesis genes at 2 weeks after MI ( Figure 6A ). The remote nonischemic tissue of the same heart was used as internal controls. FGF2, VEGF, FRT1, KDR, TGF, and PAI-1 genes showed significantly higher levels among shPHD2ϩshFIH and shPHD2 groups than the shFIH and shScramble groups ( Figure 6B ). To confirm the LCM 
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qPCR results, we also performed western blots of HIF-1␣ protein levels. Infarcted hearts were harvested at weeks 1, 4, and 8 after single-and double-shRNA therapy. Quantitative analysis of the western blots demonstrated that HIF-1␣ protein levels were significantly higher in shPHD2 and shPHD2ϩshFIH-treated hearts compared to shScramble and shFIH alone starting at week 1 (data not shown). As the minicircle vector decayed over time, protein levels also decreased progressively from week 1 to week 8 as expected (online-only Data Supplement Figure IX ). This may explain why there is no significant difference between LVEF measured at weeks 4 and 8. However, LVEF was significantly higher in both week 4 and week 8 in the double-knockdown group than in the shScramble group. At 14 days postinfarction, the double-knockdown group also had a significantly lower percentage of TUNEL-positive apoptotic cells in the periinfarct area than the shPHD2, shFIH, and shScramble groups (online-only Data Supplement Figure XII) . Finally, 1 week after minicircle shRNA delivery, the doubleknockdown group had higher HIF-2␣ protein expression in the periinfarct area (online-only Data Supplement Figure  XIII) . HIF-2␣ is another transcription factor that is stabilized in hypoxic tissue. Similar to HIF-1␣, HIF-2␣ complex binds to HREs in the promoters of many genes involved in adaptation to the hypoxic environment. In addition, several endothelial cell-specific genes (Tie-2 and Flk-1) are exclusively regulated by HIF-2␣. 26 
Discussion
In this study, we describe a novel minicircle vector that mediates double shRNA knockdown of PHD2 and FIH, resulting in upregulation of the HIF-1␣ protein in a murine model of MI. The major findings can be summarized as follows: shRNA targeting PHD2ϩFIH (1) increases BMC homing to the myocardium; (2) activates endogenous c-kit ϩ CPCs; (3) promotes myocardial neoangiogenesis; (4) de- creases cellular apoptosis; and, importantly, (5) improves cardiac function after MI. We demonstrated stable and efficient double knockdown of 2 hydroxylases using dual shRNAs inserted into novel, nonviral, minicircle vectors, resulting in upregulation of HIF-1␣. Minicircle has several advantages over both viral-based and conventional plasmid vectors. Compared with viral vectors, minicircle has a better safety profile and allows larger expression cassette and possibly easier clinical translation because of simple, goodmanufacturing practices. Compared with regular plasmid vectors, minicircle has a significantly higher level and longer duration of transgene expression both in vitro and in vivo. 27 HIF-1␣ is a master transcriptional activator that mediates the physiological response to hypoxia. In response to cardiac hypoxia, BMCs in the peripheral blood home to the site of injury, and CPCs that reside in the myocardium are activated. 28 -31 These recruited cells can regenerate damaged tissue by differentiating into endothelial cells, smooth muscle cells, and cardiac myocytes. 32 These cells also secrete angiogenic or antiapoptotic factors, which can improve the recovery of ischemic myocardium and the function of nonischemic regions. 33, 34 Mobilization of these cells is controlled by several genes, including VEGF, granulocyte macrophage colony-stimulating factor, FGF, insulin-like growth factor, erythropoietin, and stromal cell-derived factor-1; all of which are regulated by HIF-1␣. 3, 35, 36 For example, previous studies have shown that exogenous administration of granulocyte macrophage colony-stimulating factor mobilized endothelial progenitor cells from peripheral blood to the areas of ischemic injury in the hindlimb and myocardium, resulting in neovascularization. 31, 37 Similarly, activation of CPCs by injection of insulin-like growth factor has been shown to regenerate myocytes and induce vessel growth, leading to improvement in cardiac structure and function. 25 Consistent with these findings, we demonstrated that higher levels of HIF-1␣ through double shPHD2 and shFIH knockdown improved BMC homing and survival as well as enhanced activation of endogenous c-kit ϩ CPCs in the injured myocardium, resulting in increased angiogenesis and improved cardiac function. We also monitored the spatiotemporal kinetics of exogenously administered BMC recruitment to the ischemic heart after dual shRNA therapy, which to our knowledge has not been previously reported.
Unlike other approaches using single-gene therapy (eg, VEGF, FGF, insulin-like growth factor), HIF-1␣ upregulation can harnesses more cardioprotective components of the ischemic reperfusion response. The shRNA dual therapy alters the posttranslational modification of HIF-1␣, which prevents its degradation in normoxic environments and results in enhanced stem cell mobilization and increased angiogenesis. In addition to promoting potential myocyte regeneration and new vessel growth, HIF-1␣ may alter tissue metabolism and protect the myocardium against ischemic injury. 38 These potential benefits have been demonstrated in 
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studies using HIF-1␣/VP16 hybrid gene and HIF-1␣ activator proteins. 39, 40 In summary, we demonstrate a novel therapeutic approach to preserve the myocardium by harnessing the normal physiological response to hypoxia. Inhibition of HIF-1␣ degradation by dual shPHD2 and shFIH therapy produced a robust early expression of HIF-1 protein, which in turn resulted in enhanced BMC homing, activation of endogenous CPCs, increased neoangiogenesis, and decreased cellular apoptosis, leading to improvement of cardiac function after MI. Taken together, these data suggest that double knockdown of PHD2 and FIH using safe nonviral minicircle vectors may provide a promising new therapy for ischemic heart failure.
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